OverviewSuggest Edit

NovoCure engages in the development, manufacture and commercialization of tumor treating fields for the treatment of solid tumors. The Company markets its proprietary therapy, TTFields delivery system, for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. It is also involved in conducting clinical trials for the use of TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.

HQSaint Helier, JE
Employee Ratings3.6

Latest Updates

Employees (est.) (Dec 2019)782(+31%)
Revenue (FY, 2019)$351.3 M(+42%)
Share Price (Jan 2021)$170.4 (+5%)
Cybersecurity ratingAMore

Key People/Management at NovoCure

William F. Doyle

William F. Doyle

Executive Chairman
Asaf Danziger

Asaf Danziger

Chief Executive Officer, Director
William Burkoth

William Burkoth

Yoram Palti

Yoram Palti

Louis Lavigne

Louis Lavigne

Ely Benaim

Ely Benaim

Chief Medical Officer
Show more

NovoCure Office Locations

NovoCure has offices in Saint Helier, Atlanta, Boston, Charlotte and in 33 other locations
Saint Helier, JE (HQ)
Second Floor, No. 4 The Forum, Grenville St
München, DE
Elektrastraße 6
Chiyoda City, JP
1-chōme-9-1 Marunouchi
Root D, CH
D4 Pk. 6
Atlanta, GA, US
Atlanta, GA, USA
Boston, MA, US
Boston, MA, USA
Show all (38)

NovoCure Financials and Metrics

NovoCure Revenue

Embed Graph
View revenue for all periods
NovoCure's revenue was reported to be $351.32 m in FY, 2019

Revenue (Q3, 2020)


Gross profit (Q3, 2020)


Gross profit margin (Q3, 2020), %


Net income (Q3, 2020)


EBIT (Q3, 2020)


Market capitalization (8-Jan-2021)


Closing stock price (8-Jan-2021)


Cash (30-Sept-2020)



NovoCure's current market capitalization is $17.3 b.
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Cost of goods sold


Gross profit


Gross profit Margin, %

USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020



Cost of goods sold


Gross profit


Gross profit Margin, %

USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income


Depreciation and Amortization




Accounts Payable

USDQ3, 2015


0.2 x


0.1 x

Financial Leverage

1.4 x
Show all financial metrics

NovoCure Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

NovoCure Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset


out of 100

CSRHub logo

NovoCure Online and Social Media Presence

Embed Graph

NovoCure News and Updates

Acadia, Novocure & Alexion Stocks Are Out Of Favor, But Promising

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -9% year-to-date versus the S&P 500 which is up by about 7.9% over the same period. The theme remains up by about 45% since the end of 2017, versus 31% for the S&P 500. While Alexion Pharmaceuticals is down the least...

Alexion, Novocure, ACADIA: Out Of Favor Health Care Stocks Poised For Gains

The performance of the healthcare sector has been mixed this year. While dental and surgery-related stocks have declined - as Covid-19 impacts sectors that require a close person to person contact, companies working on Covid-19 vaccines have outperformed significantly...

Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer

SHANGHAI, China and ST. HELIER, Jersey, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company with a proprietary platform technology called Tumor Treatin…

Novocure Chief Science Officer Eilon Kirson to retire after 7 years in the role

Novocure Ltd. said Thursday Chief Science Officer Eilon Kirson will retire after about 7 years in the role, and 17 years with the company. The cancer treatment company said Kirson's retirement provides the opportunity to separate medical and scientific responsibilities. Uri Weinberg, vice president…
Show more

NovoCure Blogs

Novocure Announces Fourth Quarter and Full Year 2020 Preliminary Net Revenues and Provides Company Update

Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019 Novocure to present at the 39th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021 Fourth quarter and full year 2020 financial results to be r…

Novocure to Participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and address questions from analysts at …

Novocure Announces National Reimbursement in Switzerland for Optune® in Combination With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of Remedies and Equipment (MiGeL) for the treatment of patients with newly diagnosed glioblastoma (GBM), effect…

First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma

TRIDENT will test the potential survival benefit of initiating Optune concurrent with radiation therapy in patients with newly diagnosed glioblastoma Preclinical studies demonstrate that Tumor Treating Fields increase sensitivity to radiation therapy and inhibit DNA damage repair ST. HELIER, Jersey–…

Novocure to Participate in the Evercore ISI 2020 Virtual HealthCONx Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that Novocure’s Executive Chairman William Doyle and Chief Science Officer Dr. Uri Weinberg will participate in the 3rd Annual Evercore ISI 2020 Virtual HealthCONx Conference on December 1 through December 2, 2020. Mr. Doyle …

Novocure Announces 43 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2020 Virtual Annual Meeting

Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 85 percent of presentations prepared by external authors ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced 43 presentations on Tumor Treating Fields will be featured at the Society …
Show more

NovoCure Frequently Asked Questions

  • When was NovoCure founded?

    NovoCure was founded in 2000.

  • Who are NovoCure key executives?

    NovoCure's key executives are William F. Doyle, Asaf Danziger and William Burkoth.

  • How many employees does NovoCure have?

    NovoCure has 782 employees.

  • What is NovoCure revenue?

    Latest NovoCure annual revenue is $351.3 m.

  • What is NovoCure revenue per employee?

    Latest NovoCure revenue per employee is $449.3 k.

  • Who are NovoCure competitors?

    Competitors of NovoCure include PatientsLikeMe, Independa and HealthUnlocked.

  • Where is NovoCure headquarters?

    NovoCure headquarters is located at Second Floor, No. 4 The Forum, Grenville St, Saint Helier.

  • Where are NovoCure offices?

    NovoCure has offices in Saint Helier, Atlanta, Boston, Charlotte and in 33 other locations.

  • How many offices does NovoCure have?

    NovoCure has 38 offices.